Synthesis, molecular modelling, and biological evaluation of novel quinoxaline derivatives for treating type II diabetes.

ABSTRACT: Quinoxalines are benzopyrazine derivatives with significant therapeutic impact in the pharmaceutical industry. They proved to be useful against inflammation, bacterial, fungal, viral infection, diabetes and other applications. Very recently, in January 2024, the FDA approved new quinoxaline containing drug, erdafitinib for treatment of certain carcinomas. Despite the diverse biological activities exhibited by quinoxaline derivatives and the role of secretory phospholipase A2 (sPLA2) in diabetes-related complications, the potential of sPLA2-targeting quinoxaline-based inhibitors to effectively address these complications remains unexplored. Therefore, we designed novel sPLA2- and α-glucosidase-targeting quinoxaline-based heterocyclic inhibitors to regulate elevated post-prandial blood gluco

SUBMITTER: Alasmary FAS 

PROVIDER: S-EPMC11421147 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature